tirzepatide cardiovascular trial Real-world efficacy of in patients with heart failure without diabetes Tirzepatide for maintenance of bodyweight

Neurobiol Aging 36(3):14711482

Surgical therapy in the form of a properly performed hiatal hernia repair and Nissen fundoplication is indicated for stage 3 GERD patients

To use the Medicare GLP-1 Bridge benefit, patients generally need to meet all of the following: Be enrolled in Medicare Part D (a standalone prescription drug plan or Medicare Advantage plan with prescription drug coverage) Be at least 18 years old AND meet one of three BMI-based eligibility tiers (more restrictive than the general FDA label): Tier 1: BMI of 35 or higher (no additional conditions required), or Tier 2: BMI of 30 or higher WITH heart failure with preserved ejection fraction, OR uncontrolled hypertension (systolic blood pressure above 140 mm Hg or diastolic above 90 mm Hg despite treatment with two antihypertensive medications), OR chronic kidney disease stage 3a or above, or Tier 3: BMI of 27 or higher WITH prediabetes (per American Diabetes Association guidelines), previous myocardial infarction, previous stroke, or symptomatic peripheral artery disease Be using the medication in combination with current and ongoing lifestyle modification including structured nutrition and physical activity Have a prescription from a qualified prescriber (any licensed clinician with prescribing authority can prescribe

It's crucial to always check the expiration date on the packaging before using any medication, whether it's opened or unopened, to ensure it's still safe and effective

Data on the degree of transfer of GLP-1 agonist and SGLT2 inhibitors to human milk could be obtained by means of a clinical study where this transfer is measured in the milk of mothers who stopped breastfeeding